Raymond E. Cabillot Sells 6,820 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 6,820 shares of Pro-Dex stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $44.86, for a total transaction of $305,945.20. Following the sale, the director now directly owns 344,683 shares in the company, valued at $15,462,479.38. The trade was a 1.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Pro-Dex Trading Up 0.0 %

Shares of NASDAQ PDEX opened at $44.35 on Friday. The stock has a market cap of $144.58 million, a P/E ratio of 28.80 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. Pro-Dex, Inc. has a 1 year low of $16.18 and a 1 year high of $59.60. The firm has a 50-day moving average of $48.26 and a 200 day moving average of $32.95.

Institutional Trading of Pro-Dex

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC increased its position in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after buying an additional 1,028 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after acquiring an additional 900 shares in the last quarter. Bard Associates Inc. increased its holdings in shares of Pro-Dex by 17.6% during the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after acquiring an additional 2,031 shares in the last quarter. Ritholtz Wealth Management purchased a new position in shares of Pro-Dex in the 4th quarter worth about $572,000. Finally, JPMorgan Chase & Co. boosted its stake in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after purchasing an additional 529 shares in the last quarter. 15.28% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Ascendiant Capital Markets lifted their price objective on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com raised Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.